Carle Provider - Daniel H Barnett, MD, PhD

Dr. Daniel H. Barnett

Claim this profile

Carle Cancer Center

Studies Brain Tumor
Studies Renal Cell Carcinoma
11 reported clinical trials
40 drugs studied

Affiliated Hospitals

Image of trial facility.
Carle Cancer Center
Image of trial facility.
Carle Physician Group-Mattoon/Charleston

Clinical Trials Daniel H. Barnett is currently running

Image of trial facility.

Stereotactic Radiosurgery vs. HA-WBRT + Memantine

for Brain Cancer

Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) is when radiation therapy is given to the whole brain, while trying to decrease the amount of radiation that is delivered to the area of the hippocampus. The hippocampus is a brain structure that is important for memory. Memantine is a drug that is given to help relieve symptoms that can be caused by WBRT, including problems with memory and other mental symptoms. Health Canada, the regulatory body that oversees the use of drugs in Canada, has not approved the sale or use of memantine in combination with WBRT to treat this kind of cancer, although they have allowed its use in this study.
Recruiting2 awards Phase 3
Image of trial facility.

Radiation + Immunotherapy

for Head and Neck Cancer

This phase III trial compares pembrolizumab with radiation therapy to pembrolizumab without radiation therapy (standard therapy) given after pembrolizumab plus chemotherapy for the treatment of patients with squamous cell carcinoma of the head and neck that has spread from where it first started (primary site) to other places in the body (metastatic). Pembrolizumab is a type of immunotherapy that stimulates the body's immune system to fight cancer cells. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells. Radiation therapy uses high-powered rays to kill cancer cells. Giving radiation with pembrolizumab may be more effective at treating patients with metastatic head and neck cancer than the standard therapy of giving pembrolizumab alone.
Recruiting2 awards Phase 327 criteria

More about Daniel H. Barnett

Clinical Trial Related6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Daniel H. Barnett has experience with
  • Pembrolizumab
  • Stereotactic Ablative Radiotherapy
  • Radiation Therapy
  • Nivolumab
  • Axitinib
  • Cabozantinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Daniel H. Barnett specialize in?
Is Daniel H. Barnett currently recruiting for clinical trials?
Are there any treatments that Daniel H. Barnett has studied deeply?
What is the best way to schedule an appointment with Daniel H. Barnett?
What is the office address of Daniel H. Barnett?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security